Asset Details
Do you wish to reserve the book?
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Do you wish to request the book?
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
2009
Overview
Lysosomal storage diseases (LSDs) are a group of genetic disorders due to defects in any aspect of lysosomal biology. During the past two decades, different approaches have been introduced for the treatment of these conditions. Among them, enzyme replacement therapy (ERT) represented a major advance and is used successfully in the treatment of some of these disorders. However, ERT has limitations such as insufficient biodistribution of recombinant enzymes and high costs. An emerging strategy for the treatment of LSDs is pharmacological chaperone therapy (PCT), based on the use of chaperone molecules that assist the folding of mutated enzymes and improve their stability and lysosomal trafficking. After proof‐of‐concept studies, PCT is now being translated into clinical applications for Fabry, Gaucher and Pompe disease. This approach, however, can only be applied to patients carrying chaperone‐responsive mutations. The recent demonstration of a synergistic effect of chaperones and ERT expands the applications of PCT and prompts a re‐evaluation of their therapeutic use and potential. This review discusses the strengths and drawbacks of the potential therapies available for LSDs and proposes that future research should be directed towards the development of treatment protocols based on the combination of different therapies to improve the clinical outcome of LSD patients.
Publisher
Nature Publishing Group UK,WILEY‐VCH Verlag,EMBO Press,WILEY-VCH Verlag
Subject
/ Defects
/ Diabetes
/ Disease
/ Drug Evaluation, Preclinical
/ Enzymes
/ Humans
/ LSD
/ Lysosomal Storage Diseases - drug therapy
/ Lysosomal Storage Diseases - genetics
/ Lysosomal Storage Diseases - metabolism
/ Molecular Chaperones - genetics
/ Molecular Chaperones - metabolism
/ Molecular Chaperones - therapeutic use
/ Mutation
/ Patients
/ pharmacological chaperone therapy
/ Proteins
